Being healthy has been one of the biggest goal in man history. The development of medicine and medical procedures are ongoing on a exponential rate. With the pandemic we were able to realize the importance of medical treatment for the mankind. Providing the adequate procedures as fast as possible has become our priority. With than being said, experts speculate that incidents like the Corona Pandemic is likely to occur more frequently. With the adequate amount of resources we would be able to deal with the upcoming threats more wisely.
The SK Biopharmaceuticals commenced research and development of new drugs in 1993 as part of their search for the next-generation growth engine of SK Group. The exciting ascent of SK Biopharmaceuticals began with opening the company’s first Investigational New Drug Application (IND) with the FDA, the clinical trial of a new candidate drug substance in 1996. Since then, the company has focused on the development of treatments for central nervous system (CNS) disorders and accomplished the following milestones: The company became ▲the first Korean company independently develop an investigational anti-epileptic drug through to an FDA approval (cenobamate), ▲a company that has made a successful out-licensing deal to commercialize its investigational anti-epileptic drug in Europe (cenobamate), ▲the first Korean company to discover and develop a compound to treat a CNS disorder, which was licensed out, and eventually approved by the FDA and EMA (solriamfetol). In addition, the company recently began research for the development of drugs to treat brain tumors, including metastatic tumors, based on our experience accumulated in research and development of treatments for brain disorders.
Currently, SK Biopharmaceuticals is conducting basic research for the development of innovative new drugs at the Life Science Research Institute in Pangyo Techno Valley in Gyeonggi Province. Further, SK Life Science, Inc. in Paramus, New Jersey, USA, is pursuing global clinical development and marketing. In addition, SK Bio-pharm Tech. Company, Ltd. in Shanghai, China is striving to secure opportunities for local strategic alliances to advance development and commercialization in China.
SK Biopharmaceuticals aims to grow into a Fully Integrated Global Pharmaceutical Company (Global FIPCO), equipped with an entire value chain ranging from development and manufacturing to commercialization via its own sales and marketing organization.
- By Yujin Kong (Academic Affairs Department)